Lilly, Strides Arcolab enter partnership to deliver generic cancer drugs in emerging markets


Hannah Blake


Eli Lilly has announced a collaboration with India’s Strides Arcolab, to jointly manufacture and distribute generic cancer drugs for developing markets.

Under terms of the agreement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, based in Bangalore, India. Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these medications in multiple geographies across the emerging markets.

“Cancer medicines of the highest quality continue to be an unmet need in many markets around the world. Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets.”

Jacques Tapiero, Lilly Senior Vice President and President of its emerging markets division.

In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future.




Related news:

India's Strides Arcolab, Eli Lilly in generic cancer drug tie-up (Reuters)

Eli Lilly to Market Strides Arcolab's Cancer Drugs (Wall Street Journal)

Reference links:

Strides Arcolab press release

profile mask


10 December, 2012